THE FOUNDING TEAM
LEROY HOOD, M.D., Ph.D. Professor and co-founder of the Institute for Systems Biology and CEO of Phenome Health. Hood invented automated DNA sequencing, was a leader in human genome sequencing and a pioneer in systems biology. Hood was awarded the Presidential Medal of Science in 2011. Hood is ia cofounder of Amgen and numerous biotech companies. He has pushed several paradigm-shifts in biology and medicine, including championing deep phenome profiling and the creation of P4 Medicine, a new paradigm of population health. Hood's Phenome Health initiative will provide P4BIOS with a wealth of data on disease mechanisms.
STUART KAUFFMAN, M.D., Emeritus professor of Biochemistry & Biophysics at the University of Pennsylvania and former faculty of the Santa Fe Institute. A world leader and pioneer in complex systems (biocomplexity), Kauffman was the founder of BiosGroup and has inspired many generations of theoretical biologists and physicists. He is currently affiliate faculty at the Institute for Systems Biology. Kauffman holds the first patent on random DNA, RNA and peptide libraries and along with his foundational contribution to cell state dynamics, his work motivates P4BIOS's technology.
SUI HUANG, M.D, Ph.D., Professor at the Institute for Systems Biology in Seattle. Huang, a molecular biologist, is a pioneer in integrating complex systems theories to biomedical sciences. A world-leader in non-genetic dynamics of cells in cancer, he has fought reductionist approaches in cancer treatment and promoted a more encompassing complexity sciences view of cancer. Huang as multiple advised biotech startups and pharma investors. He currently leads multi-omics analysis of cancer and other disease, and several programs applying AI to biomedical research. Huang is the founding/interim CSO of P4BIOS (see below)
SONIA LAIN, Ph.D., Professor in Molecular Cancer Pharmacology at the Department of Microbiology, Tumor and Cell Biology of the Karolinska Institute in Stockholm. She is an expert in bioassay design and leads early-stage development of a novel class of cancer drugs. She provides P4BIOS with solid experience in phenotypic assays and drug development.
INGEMAR ERNBERG, M.D. Ph.D., Professor of tumor biology at the Karolinska Institute, is a world-leading expert in virus biology and tumor biology. Ernberg now spearheads “Precision Medicine” efforts in Sweden to translate multi-omics advances to patient cancer care. With his uniquely broad knowledge of the cutting edge of molecular medicine gained through decades of leadership at the Karolinska, Ernberg brings a critical perspective to keep P4BIOS on track towards practical translation.
ANDERS HÄRFSTRAND, Chairman of Härfstrand Consulting AG. He is a former pharma executive and expert in Commercial Operations in Pharmaceuticals, Biotech Business, Fundraising and M&A. Härfstrand is currently an advisor in the pharma industry and holds several board positions in private and listed companies.
ERIK MOSBERG is co-founder of Planetary Balance AB, and the Chairman and CEO of the company. With decades of experience in large corporations sales and management, Moberg is the founding/interim CEO of P4BIOS (see below)
BOARD
ERIK MOSBERG (Chairman)
LEROY HOOD | STUART KAUFFMAN | INGEMAR ERNBERG
​
​
MANAGEMENT
CEO (interim):
Erik Moberg, Co-founder. ​​​
​CSO (interim):
Sui Huang, Co-founder
​
​
CFO (interim):
Angelika Zacher​​
​
​
Erik Moberg brings decades of senior leadership experience from the IT industry, including roles at IBM, Oracle, Fujitsu, and EDS. A specialist in the Nordic market, he has a proven track record of introducing and scaling novel IT and Big Data solutions. Erik is a seasoned deal-maker, recognized for architecting and executing the most complex, high-value transactions in his companies' histories. At P4Bios, he leverages this expertise to forge strategic alliances and commercial foundations necessary to bring disruptive biomedical innovations to the global market.
Sui Huang brings the classical expertise in expression gene cloning, gene libraries to P4BIOS. With intricate knowledge in disease and drug mechanisms grounded in biocomplexity, he will help P4BIOS break new grounds while utilizing solid gene cloning methodology. He has led large multi-disciplinary systems biology/AI-driven approaches in the life sciences with a keen sense for leveraging basic science for translational needs.
Angelika Zacher brings over 26 years of financial, operational, and legal leadership to P4Bios, with more than half of her career dedicated to the medical industry. As a purpose-driven CFO, she constructs the financial and legal frameworks necessary to scale scientific innovation into market-ready technologies. Angelika led global operations with turnovers up to CHF 5.6B at Abbott, Johnson & Johnson, and Migros. Having advised various startups, she provides the structural guidance essential for early-stage growth. She integrates an MBA from Kellogg and Law degrees from Cambridge, Zurich, and St. Gallen with U.S. CPA expertise to drive P4Bios.